ostarine
ANABOLIC · NONSTEROIDAL SARM · ORAL · T½ ~22 H
also: MK-2866 · GTx-024 · S-22
Enobosarm is the most extensively studied non-steroidal SARM, with randomised placebo-controlled phase 2 and phase 3 data in cancer-associated muscle wasting and phase 2 data in AR-positive breast cancer. It has consistently increased lean body mass relative to placebo, but has repeatedly failed to demonstrate corresponding improvement in physical function, and no regulator has approved it for any indication.
// our evidence grade — unedited
The only compound in this group with completed randomised phase 3 human trials, but both POWER trials missed their FDA-agreed co-primary responder endpoints and the drug remains unapproved anywhere.
We grade this compound and we sell it. The grade is set against our published criteria before any stocking decision and is not adjusted because it is in the catalogue.
read the full evidence →// specification
| full name | Enobosarm (ostarine, MK-2866, GTx-024, S-22) |
| cas | 841205-47-8 |
| formula | C19H14F3N3O3 |
| molar mass | 389.3 g/mol |
| purity | ≥ 98% HPLC |
| form | research solution |
| storage | Reference material: store as a solid, desiccated and protected from light, at -20 °C for long-term stability; solutions in organic solvent are typically stored at -80 °C and freeze-thaw cycles minimised. |
| solubility | Lipophilic small molecule; soluble in DMSO, ethanol and DMF, poorly soluble in aqueous buffer. Vendor certificate-of-analysis solubility figures vary and should be taken from the specific lot. |
// select size
crypto payment · research use only · not for human consumption
// others in Anabolic & Receptor